Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis  by da Rocha, Antonio José et al.
rev bras hematol hemoter. 2 0 1 6;3 8(1):44–54
www.rbhh.org
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
Review article
Modern  techniques  of  magnetic  resonance  in the
evaluation of primary  central  nervous  system
lymphoma: contributions  to the diagnosis  and
differential diagnosis
Antonio José da Rochaa,b,∗, Bruno Vasconcelos Sobreira Guedesb,
Talita  Maira Bueno da Silveira da Rochab, Antonio Carlos Martins Maia Juniora,b,
Carlos  Sérgio Chiattonea
a Fleury Medicina e Saúde, São Paulo, SP, Brazil
b Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 1 July 2014
Accepted 30 November 2015









a  b  s  t  r  a  c  t
In addition to ﬁndings from conventional magnetic resonance imaging, modern mag-
netic resonance imaging techniques have provided important information about tumor
metabolism, in vivo metabolite formation, water molecule diffusion, microvascular density,
and  blood-brain barrier permeability, all of which have improved the in vivo diagnostic accu-
racy  of this method in the evaluation of primary central nervous system lymphoma. These
nonconventional magnetic resonance techniques are useful in the clinical practice because
they enhance conventional magnetic resonance imaging by reinforcing the possibility of a
diagnosis and by allowing the early detection of disease recurrence.
This  report is a review of the most relevant contributions of nonconventional magnetic res-
onance techniques to the imaging diagnosis of primary central nervous system lymphoma,
the differential diagnosis of this disease, and the prognosis of patients. This paper aims to
describe a wide range of presentations of primary central nervous system lymphoma, their
appearance in imaging, and the differential diagnoses of this disease.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.IntroductionPrimary central nervous system lymphomas (PCNSL)
have a predictable imaging appearance in their classical
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reserved.presentation. Conventional magnetic resonance imaging
(MRI) features can be suggestive of PCNSL but are nota Cesário Motta Junior, 112, Vila Buarque, 01221-020 São Paulo, SP,
speciﬁc. Because of the form of presentation, the list of
differential diagnoses is long, and mainly includes inﬂamma-
tory/infectious diseases particularly of the central nervous
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ystem (CNS), toxoplasmosis in AIDS patients, and primary
nd secondary malignancies.1–3
Modern techniques of magnetic resonance have increased
he clinical applicability of this imaging method because
hey provide important information about tumor metabolism,
n vivo metabolite formation, water molecule diffusion,
icrovascular density, and blood–brain barrier (BBB) per-
eability. Although histology and an investigation of the
erebrospinal ﬂuid for meningeal disease are still the gold
tandard in the diagnosis of CNS lymphoma, these advanced
echniques can improve the diagnostic accuracy of PCNSL,
articularly when the brain parenchyma is affected.1,4–9
This report is a review of the most relevant contributions of
dvanced MRI  techniques to the imaging diagnosis of PCNSL,
he differential diagnosis of this disease, and the prognosis of
atients.
ontribution  of  nonconventional  magnetic
esonance  techniques  to  the  diagnosis  of
rimary  central  nervous  system  lymphoma
nd the  prognosis  of  patients
he various imaging methods that are currently available no
onger exclusively provide descriptive anatomical informa-
ion. Now advanced imaging techniques allow an assessment
f functional parameters, thereby maximizing the potential
f these techniques for an accurate diagnosis and treatment
ssessment.
Despite treatment advances, survival among PCNSL
atients in the United States has remained poor. However, sur-
ival has improved over time in the subset of PCNSL patients
ho  are human immunodeﬁciency virus (HIV)-negative.10
Nonconventional MRI  techniques are useful in the clin-
cal practice because they enhance conventional MRI by
einforcing the possibility of a diagnosis of PCNSL, by con-
ributing to the prognosis of patients, and by allowing the early
etection of disease recurrence.1,8,11
iffusion-weighted  imaging
iffusion-weighted imaging (DWI) reﬂects the macromolecu-
ar motion of intra- and extracellular water and is helpful in
istinguishing between PCNSL and other tumors and tumor-
imicking lesions. Due to the hypercellularity of PCNSL, water
iffusion is often restricted, which makes these tumors appear
yperintense on DWI and hypointense on apparent diffu-
ion coefﬁcient (ADC) maps. A decreased ADC value indicates
ncreased cellularity.4,8,12 The technique that is generally used
o determine the ADC value involves calculating the ADC ratio
f the solid component of the tumor and comparing this ratio
o that of the normal-appearing white matter. Restricted diffu-
ion with an ADC threshold value ≤1.1 × 10−3 mm2/s has been
ecommended to differentiate PCNSL from other intracra-
ial focal lesions.7 An ADC threshold value >1.6 × 10−3 mm2/s
ncreases the probability of a diagnosis of toxoplasmosis over
CNSL in immunocompromised patients. However, there has
een signiﬁcant overlapping in these values in necrotic ring-
nhancing lesions.4,132 0 1 6;3 8(1):44–54 45
A recent report revealed that low ADC  values in pre-
therapeutic tumors were predictive of shorter progression-
free survival and overall survival. Furthermore, increasing
ADC values during treatment suggest a positive response
to therapy, whereas decreasing ADC values suggest tumor
progression.12
Diffusion tensor imaging (DTI) takes advantage of highly
ordered white matter ﬁbers, which have a directionally
ordered structure due to preferential water diffusion along
the longitudinal axis of axons and myelin sheaths. This tech-
nique has recently emerged as a sensitive tool for the detection
of alterations in the structure of white matter. Additionally,
different degrees of cellularity and cellular organization may
affect the fractional anisotropy (FA) value. The FA values for
PCNSL are signiﬁcantly lower than those for glioblastoma;
therefore, these values can help in the differentiation of these
tumors.14
Further studies that combine histological correlation tech-
niques with imaging ﬁndings are needed to determine the
impact of the measurement of ADC on patient prognosis and
treatment planning. However, we  recommend performing a
careful ADC analysis of different solid parts of the tumor
before treatment and after treatment as an additional non-
invasive tool to estimate local in vivo responses.
Perfusion-weighted  imaging
Perfusion MRI can be used to estimate the nutritive deliv-
ery of arterial blood to the capillary bed in biological tissue
using signal intensity–time curves to determine the capillary
density in dynamic susceptibility contrast (DSC) T2-weighted
echoplanar sequences. The post-processing of acquired data
allows for a semiquantitative analysis of physiological param-
eters, particularly of the relative cerebral blood volume (rCBV),
relative cerebral blood ﬂow (rCBF), and time-to-peak (TTP).
Another perfusion MRI technique that can be used to evaluate
vascular permeability in a dynamic contrast-enhanced (DCE)
T1-weighted sequence is to simultaneously administer an
intravenous injection of a paramagnetic agent (gadolinium).
PCNSL are associated with mildly increased or occasionally
decreased perfusion that is usually higher than that in most
focal brain inﬂammatory, demyelinating and infectious dis-
eases but lower than that in high-grade gliomas (rCBV > 1.75).7
PCNSL lesions are usually strongly enhanced due to the dis-
ruption of the BBB and the fast leakage across the BBB;
however, these lesions show a low rCBV, which is in agreement
with histological data that demonstrate a lack of neoangio-
genesis in lymphomas, mainly when they are highly cellular
or there is considerable perivascular or intravascular tumor
inﬁltration.5
The percentage of signal intensity that is recovered at the
end of the ﬁrst pass of the contrast agent relative to base-
line is associated with contrast agent leakage, the size of the
intravascular space, and the rate of blood ﬂow. It is shown
as a characteristic signal intensity–time curve on DSC-MRI.
The mean percentage of signal intensity recovery is high
(113.15 ± 41.59) in lymphomas, intermediate in glioblastomas
(78.22 ± 14.27), and low in metastases (53.46 ± 12.87). This
value is an additional sensitive and speciﬁc MRI parameter
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Figure 1 – Diffuse large B-cell lymphoma in the corpus callosum. An axial T1 image after intravenous gadolinium
administration (A) shows a homogeneous enhanced mass in the splenium of the corpus callosum, which is predominantly
in the right hemisphere (arrow). An axial apparent diffusion coefﬁcient map  (B) conﬁrmed a very low signal intensity in the
solid lesion. Note the hyperintensity of the perilesional vasogenic edema. Proton magnetic resonance spectroscopy (C)
shows decreased N-acetylaspartate levels and high choline/N-acetylaspartate and choline/creatinine ratios. Note the
increased lipid and lactate peaks (0.9–1.3 ppm). A magnetic resonance perfusion sequence (dynamic susceptibility contrast
magnetic resonance image T2*) (D) conﬁrmed the absence of neoangiogenesis (low relative cerebral blood volume). Note the
high percentage of signal intensity recovery (the ascending part of the curve above the baseline as indicated by the vertical
arrowheads).
that can be used to differentiate between malignant brain
tumors.6
Perfusion computed tomography (CT) is available but
involves ionizing radiation and a more  limited area of the
brain. In contrast to MRI, only a few studies have been
published on perfusion CT in brain tumors. However, the diag-
nostic value of perfusion CT in brain tumors may increase in
the future due to its advantages related to spatial resolution
and the linear correlation between the contrast concentration
and the attenuation of the tissue.15
Magnetic  resonance  spectroscopyProton magnetic resonance spectroscopy (MRS) allows for
the semiquantitative evaluation of in vivo tissue to measuremetabolites, such as N-acetylaspartate (NAA), choline (Cho),
creatinine (Cr), lactate (Lac), and lipids (Lip). In PCNSL,
MRS has demonstrated elevated Lip and Lac peaks, high
Cho/Cr ratios, decreased NAA levels and high Cho/NAA ratios
(Figure 1).4,11,16,17 The presence of Lac or Lip at baseline
has been associated with poor progression-free and overall
survival.11
PCNSL grow rapidly and behave similar to high-grade brain
tumors with evidence of high cell membrane turnover on MRS
(a high Cho peak), neuronal damage (decreased NAA levels),
and anaerobiosis (high lactate levels).4,11,16,17 These ﬁndings
are similar to those for high-grade gliomas and metastases;
however, the presence of this MRS pattern may help in the
differential diagnosis of brain toxoplasmosis in immunocom-
promised patients, which typically exhibits elevated Lip peaks
and no signiﬁcant increases in Cho or its ratios.1,4,11
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Table 1 – Findings obtained using nonconventional magnetic resonance techniques that are useful for differentiating
PCNSL from mimic  lesions.
Primary central nervous system lymphoma
Diffusion-weighted imaging Restricted water molecule movement (typically homogeneous in
immunocompetent patients)
Apparent diffusion coefﬁcient value ≤1.1 × 10−3 mm2/s
Proton magnetic resonance spectroscopy Increased lipid and lactate levels (0.9–1.3 ppm)
Increased choline levels and decreased N-acetylaspartate levels
Dynamic contrast-enhanced magnetic resonance imaging High permeability of the blood-brain barrier may be observed
Dynamic susceptibility contrast magnetic resonance imaging Lower relative cerebral blood volume (<1.75) than in high-grade
gliomas or metastases
A high percentage of signal-intensity recovery above the baseline
would favor a diagnosis of lymphoma.
Note:  All of these features should be carefully interpreted in immunocompromised patients due to the occurrence of necrosis and hemor-




































he early diagnosis of PCNSL is crucial to deﬁne therapeutic
rocedures. When PCNSL are suspected based on imaging, a
issue biopsy is mandatory and gross tumor resection must
e avoided.18 The nonconventional MRI  features of PCNSL
Table 1) and mimicking brain lesions should be known in
rder to support the suspicion.
he  imaging  features  of  primary  central
ervous  system  lymphoma  and  other  focal
rain  lesions  and  the  differential  diagnosis  of
hese  lesions
CNSL is associated with a higher nuclear-to-cytoplasm ratio
nd a relatively low intratumoral water content, which indi-
ate prominent CT hyperdensity and hypointensity signals in
2-weighted images. These imaging features are important for
istinguishing between PCNSL and other focal brain lesions
hat usually demonstrate a higher water content (hyperin-
ense on T2-weighted images) such as gliomas, metastases,
nd tumefactive demyelinating lesions.14,19
Neurosarcoidosis rarely presents as a brain tumor-like
esion but exhibits hyposignal intensity on T2-weighted
mages and disseminates perivascularly with variable contrast
nhancement without necrosis. Therefore, the differential
iagnosis of PCNSL is crucial.
Metastatic diseases related to melanoma and renal cell,
reast, and lung carcinomas are more  likely to have blood
roducts than PCNSL. Moreover, in contrast to PCNSL, brain
etastases are usually located at the gray-white matter junc-
ions (hematogenously disseminated) and they often incite
arked peritumoral edema.1
Several high-grade gliomas may exhibit hyposignal inten-
ity on T2 and often contain blood products with inﬁltrated
argins and heterogeneous contrast enhancement, which
akes it difﬁcult to differentiate gliomas from lymphomas.
he classical ‘mirror image’ or ‘butterﬂy pattern’ that is
ue to the symmetrical involvement of the genu or the
plenium of the corpus callosum has been observed inPCNSL.14 Subependymal disease may occur in both PCNSL and
high-grade glioma.1 PCNSL lesions often have more  restricted
diffusion and lower ADC values than high-grade gliomas and
metastases.8
Peripheral enhancement patterns of PCNSL, including
‘ring-like’ and ‘open ring-like’ aspects, must be distinguished
from those of classical brain demyelination.19 PCNSL have
solid portions with thicker and non-uniform enhancement,
which is not restricted to periventricular zones but affects
deep gray matter as a single lesion or multiple lesions.20
Moreover, high Cho levels and Cho ratios (Cho/NAA > 1.9) on
MRS,  areas of restricted water molecule diffusion on DWI,
the absence of high rCBV levels (<1.75) and a high per-
centage of signal intensity recovery above the baseline on
DSC-MRI would favor a PCNSL diagnosis over other diagnostic
possibilities.4,6,7,11,17
When PCNSL are suspected, corticotherapy should be
avoided or discontinued because tumor shrinkage results in
radiographic regression in approximately 40% of patients (‘the
vanishing tumor’), which is suggestive of PCNSL (Figure 2). The
detection of a ‘vanishing tumor’ should not be considered in
the diagnosis of PCNSL because sarcoidosis, brain demyelina-
tion, acute encephalomyelitis, and other malignancies (more
rarely) can exhibit dramatic responses to steroids.3,18
A DTI analysis may be used to distinguish between PCNSL
and glioblastoma. A quantitative analysis of FA and ADC val-
ues found that these values were signiﬁcantly decreased when
the solid portions of the tumors were compared with normal-
appearing white matter in the contralateral hemisphere. The
FA and ADC values in primary cerebral lymphoma were sig-
niﬁcantly lower than those in glioblastoma.14
The MRS ﬁndings for PCNSL, high-grade gliomas and tume-
factive demyelinating lesions may be similar; therefore, we
recommend a careful interpretation of this technique. It is use-
ful to consider all of the conventional and nonconventional
features to support the clinical presumption of each disease,
to make a histological diagnosis, and to deﬁne therapeutic
procedures.1,4,6,7Distinguishing between PCNSL and infectious brain lesions
is difﬁcult but clinically relevant, particularly in immuno-
compromised patients. In this setting, nonconventional MRI
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Figure 2 – Corticotherapy effects in a primary central nervous system lymphoma. An axial T1 image after intravenous
gadolinium administration (A) shows multifocal primary central nervous system lymphoma as deep homogeneous
enhanced masses in the corpus callosum, which are adjacent to the third ventricle (arrowheads). A comparative
T2-weighted image (B) depicts nodular hypointensity in the lesions with perilesional vasogenic edema (arrowheads). A
comparative T1 image after intravenous gadolinium administration (C) was obtained after corticotherapy and demonstrated
evident tumor shrinkage (‘vanishing tumors’).may be used to differentiate focal brain lesions in PCNSL
from neurotoxoplasmosis, cryptococcosis, tuberculosis and
intracranial abscesses.21 DWI with ADC maps is useful to
distinguish between toxoplasmosis and PCNSL. Early toxo-
plasmosis may be associated with areas of restricted diffusion
on DWI; however, toxoplasmosis lesions have signiﬁcantly
greater diffusion than in PCNSL. ADC ratios that ranged from
1.0 to 1.6 have been reported for both PCNSL and toxoplas-
mosis, whereas ADC ratios greater than 1.6 were associated
solely with toxoplasmosis.13 In addition, toxoplasmosis may
be indicated by the presence of Lip and Lac and a decrease in
the NAA/Cr ratio on MRS.  Conversely, markedly elevated Cho
levels would favor a PCNSL diagnosis.4,11 The accuracy of MRS
is inversely proportional to the extension of necrosis (Figure 3).The conventional and nonconventional MRI  and patholog-
ical features of CNS post-transplantation lymphoproliferative
disorder (PTLD) are similar to those of PCNSL and have been
observed in immunocompromised patients.22–24 An imaging
pattern that is associated with CNS PTLD includes peripherally
enhancing intraparenchymal lesions, which are usually multi-
focal supratentorial masses that may extend to the ependymal
surface leptomeninges with nodular enhancement. Imaging
plays a crucial role in diagnosing disease, guiding biopsy and
monitoring disease responses following therapy.25
After solid organ transplantation, patients are at risk
of developing several neurological complications, including
neurotoxicity due to immunosuppressive drugs, seizures,
encephalopathy, stroke, opportunistic infections, and PTLD.24
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Figure 3 – A focal brain lesion in an AIDS patient (toxoplasmosis versus lymphoma). An axial T1 image after intravenous
gadolinium administration (A) shows a large periventricular lesion in the left thalamus with extensive necrosis (asterisk)
and thick peripheral enhancement. An axial apparent diffusion coefﬁcient map  (B) conﬁrmed a very low signal intensity in
the solid portion of the lesion (arrowheads) compared with the central area of necrosis (asterisk). Additionally, note the
hyperintensity of the perilesional vasogenic edema. Proton magnetic resonance spectroscopy (C) conﬁrmed the presence of
elevated lipid and lactate (0.9–1.3 ppm) and choline levels with reduced N-acetylaspartate levels. A magnetic resonance
perfusion sequence (dynamic susceptibility contrast magnetic resonance image T2*) (D) conﬁrmed the absence of













meningiomas (Figure 4).1,26–28ecause of immunosuppression, transplant patients are at
isk for developing several CNS infections that may lead to
eningitis, encephalitis, and focal abscesses. Several CNS
nfections share many  overlapping imaging features with
TLD, particularly in the ﬁrst months after transplantation.
onconventional MRI  helps the prompt diagnosis of disease,
he guidance of biopsy and the initiation of appropriate treat-
ent.
eculiar  presentations  of  primary  central
ervous  system  lymphomaseptomeningeal inﬁltration in the course of lymphoma, par-
icularly in systemic disease, is not rare. However, thisimaging appearance is nonspeciﬁc and may alternatively
occur after CNS invasion by infection or in several other
primary and systemic malignancies (meningeal carcino-
matosis). Associated periventricular masses, mainly with
subependymal inﬁltration, may corroborate a diagnosis of
CNS lymphoma in a differential diagnosis.1 Dural-based lym-
phoma, particularly the mucosa-associated lymphoid tissue
(MALT) subtype, mimics meningiomas; therefore, a careful
interpretation of imaging ﬁndings in the clinical scenario is
recommended. Few reports have described the typical presen-
tation of intracranial MALT  lymphoma-mimicking globularThe diagnostic possibility of a cranial vault lymphoma is
greater when the lesion involves the scalp, the skull bone, and
50  rev bras hematol hemote
Figure 4 – Mucosa-associated lymphoid tissue (MALT)
lymphoma mimicking meningioma. A sagittal T2-weighted
image (A) shows a solid extra-axial lesion that inﬁltrated
the dura mater in the parietal region (arrowheads). A
comparative image on a T1-weighted sequence after
intravenous gadolinium administration (B) conﬁrmed
homogeneous contrast enhancement that was associated
with an extensive dura tail, which mimicked the
appearance of a meningioma (arrowhead).
the pachymeninges, mainly in the absence of bone erosion
(Figure 5). However, this pattern of lesion is not speciﬁc to
PCNSL because it has been observed in systemic lymphoma
and in many  mimic  lesions, including metastatic inﬁltration
from prostate carcinoma and breast cancer, osteomyelitis,
meningioma, plasma cell tumors, and histiocytosis.29
A non-enhancing presentation of PCNSL was found in 1%
of patients in a large series of immunocompetent patients and
was documented in immunocompromised patients.21,30,31‘Lymphomatosis cerebri’ is frequently misdiagnosed as
diffuse nonspeciﬁc leukoencephalopathy, Binswanger’s dis-
ease (subcortical ischemic vascular dementia), infectiousr. 2 0 1 6;3 8(1):44–54
encephalomyelitis including progressive multifocal leukoen-
cephalopathy, toxic or metabolic abnormalities, unknown
autoimmune diseases, or neoplasms such as gliomatosis
cerebri.9,32–35 DWI and MRS may support a presumptive diag-
nosis of brain inﬁltrative neoplasia; however, an accurate
diagnosis is only possible after a brain biopsy.36 MRS  may show
increased Cho levels and Cho ratios (Cho/NAA > 1.9), which
suggest inﬁltrative neoplastic disease (Figure 6).35 DWI is vari-
able and can depict heterogeneous areas with restricted water
molecule movement. Perfusion MRI  techniques are not help-
ful because the rCBV is not increased and there is no abnormal
permeability of the BBB.
Intravascular lymphoma is often misdiagnosed as multifo-
cal demyelination, septic encephalopathy, infectious lesions,
or multifocal and recurrent strokes due to embolic diseases
or CNS vasculitis (systemic or primary angiitis).34,37 Cere-
bral angiography may reveal multivessel segmental stenoses
and dilatations (‘bead-like pattern’) that are consistent with
vasculitis.38 Intravascular lymphoma may follow a relapsing-
remitting or relapsing-progressive clinical course due to
ﬂuctuating ischemic damage caused by the small vascu-
lar occlusions.1,37 A correct presumptive diagnosis may be
supported by persistent and progressive DWI abnormalities
that are associated with variable gadolinium enhancement.36
An extensive imaging investigation is not enough to con-
ﬁrm intravascular lymphoma, and an early brain biopsy is of
paramount importance to achieve a deﬁnitive diagnosis and
to deﬁne therapeutic procedures.37,39,40
When primary intraocular lymphomas are considered, the
imaging features are not speciﬁc and are frequently inconclu-
sive. Conversely, the imaging features of orbital lymphomas
often mimic  other diseases. These diseases include metastatic
disease, inﬂammatory pseudotumors, sarcoidosis, histio-
cytosis including Erdheim-Chester disease, meningiomas,
cavernous hemangioma, ocular melanomas, and primary
lacrimal gland lesions.1,41 In contrast to orbital pseudotumors,
primary orbital lesions are painless.42
A DWI analysis is useful to distinguish between lym-
phomas and idiopathic orbital inﬂammatory pseudotumors,
optic nerve sheath meningiomas and gliomas.43,44 The supe-
rior lateral quadrant and the extraconal space are typical
locations of orbital lymphomas. An intriguing pattern is char-
acterized by the inﬁltrative behavior of the tumor, which
shapes the contour of the eyeball and typically crosses the
bony limits. Osteolysis may not be present. Effective treat-
ment responses were observed in the follow-up imaging of
orbital lymphomas; however, several cases of local relapse
were found.45
Neurolymphomatosis is extremely rare; therefore, this
diagnostic possibility is often overlooked. This disease is
often misdiagnosed as chronic inﬂammatory demyelinating
polyneuropathy. The possibility of concomitant lymphoma
arises when thickened cranial nerves, cauda equinae roots
and/or peripheral nerves are demonstrated, particularly on
MRI. Neurolymphomatosis should be considered in various
types of neuropathy even when the diagnostic criteria for
chronic inﬂammatory demyelinating polyneuropathy are met,
particularly in patients who complain of pain.46
Metastatic tumors, including systemic lymphoma, may
affect the leptomeningeal compartment with cranial nerve
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Figure 5 – A cranial vault lymphoma. An axial T2-weighted image (A) shows a small multicompartmental lesion in the
occipitoparietal region (arrow). Axial diffusion-weighted imaging (B) shows restricted water molecule diffusion in the solid
portions of the lesion. A comparative T1 image after intravenous gadolinium administration (C) shows an enhanced lesion
that involves the scalp, the skull bone, and the pachymeninges and extends to the leptomeninges (arrowhead). A













sr root thickening and variable contrast enhancement that
imics the imaging appearance of neurolymphomatosis.
dditionally, hypertrophy of the cauda equina nerve roots
s a nonspeciﬁc ﬁnding and may be observed in hereditary
nd acquired demyelinating neuropathies or in secondary
eoplasias due to inﬁltration of the nerve roots by the
eoplasm. Hypertrophy of the cauda equina nerve roots has
een described as a likely paraneoplastic phenomenon in an
lderly patient with lymphoplasmacytic lymphoma.47 In cer-
ain circumstances, the imaging pattern of neuroﬁbromatosis
ay mimic  the pattern of neurolymphomatosis; however,
nderstanding the systemic features of this neurocutaneous
yndrome will be useful to make an accurate diagnosis.Primary lymphoma is a rare cause of myelopathies.
Spinal MRI  has demonstrated multifocal lesions with typical
homogeneous gadolinium enhancement. Conus medullaris
or cauda equina involvement is characteristic of primary
intramedullary spinal cord lymphoma; however, a patholog-
ical conﬁrmation often requires a CNS biopsy.48,49 Lymphoma
of the spine may often occur in the bony, extradural-epidural,
intradural extramedullary, or intradural intramedullary com-
partments and may mimic  several different diseases. These
diseases include metastatic tumors, infectious diseases
particularly tuberculosis and epidural empyema, and inﬂam-
matory conditions, such as sarcoidosis and demyelinating
lesions.
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Figure 6 – Lymphomatosis cerebri in an immunocompetent patient. An axial ﬂuid-attenuated inversion recovery image (A)
shows unspeciﬁc diffuse hyperintense areas on both brain hemispheres that cross the splenium of the corpus callosum
with no mass effect. No contrast enhancement was observed (not shown). A comparative ﬂuid-attenuated inversion
recovery image (B) was obtained after two months without speciﬁc therapy conﬁrming the extensive progression of the
disease, and exhibiting conﬂuent hyperintensity of both brain hemispheres, predominantly of the left. Minimal mass effect
and no gadolinium-enhanced areas were  observed. A proton magnetic resonance spectroscopy study (C) was useful to
support a presumptive diagnosis and demonstrated increased choline levels and an increased choline/N-acetylaspartate
arta
r
2008;18(4):411–7.ratio (>1.9), which were associated with reduced N-acetylasp
Conclusions
PCNSL are distinctive and rare presentations of certain sub-
types of lymphoma, generally the non-Hodgkin diffuse large
B-cell type, and contrast-enhanced MRI  is the imaging tech-
nique of choice to evaluate most patients and their variable
presentations.
Modern neuroimaging techniques may help us suspect
PCNSL earlier, which would result in timely treatment and less
CNS damage. Radiologists and hematologists must be familiar
with the role of these new advanced techniques, which may
help in the differentiation of PCNSL and other mimic  lesions.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.te levels and elevated lactate peaks.
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